Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GUTS
Strong SellSinkerFractyl Health, Inc. · Healthcare · United States · $105M · Avg Vol: $884K/d
COMPANY DESCRIPTION
Fractyl Health, Inc. is a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, including type 2 diabetes and obesity. The company's competitive moat is centered on its proprietary Revita system, a duodenal mucosal resurfacing procedure, and its Rejuva gene therapy platform. It operates as an innovative niche player aiming to transform the treatment paradigm for chronic metabolic conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.1M | 93.0K | 0 | -22.5% | — | 22.4M | 522.0% |
| EPS | -0.40 | -0.60 | -0.50 | -0.92 | — | -0.91 | — | — |
| Shares | 158.6M | 158.6M | 158.6M | 153.4M | -3.3% | 159.2M | — | — |
| Debt | 19.5M | 86.4M | 62.5M | 61.6M | 46.8% | 60.7M | — | — |
| Equity | -252.3M | -325.1M | 28.4M | 9.5M | -66.7% | — | — | — |
| Op CF | -46.2M | -42.8M | -65.5M | -90.3M | — | -82.4M | — | — |
| Inv CF | -56.0K | -0.4M | -1.8M | -0.6M | — | — | — | — |
| Fin CF | 4.3M | 27.4M | 101.2M | 105.0M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GUTS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GUTS | Fractyl Health, Inc.(you) | $105M | 14 | Strong Sell |
| ANIX | Anixa Biosciences, Inc. | $118M | 14 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| BMEA | Biomea Fusion, Inc. | $125M | 16 | Strong Sell |
| VTVT | vTv Therapeutics Inc. | $128M | 18 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| AARD | Aardvark Therapeutics, Inc. | $127M | 18 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%